This policy describes coverage criteria, limitations, and background for epidermal nerve fiber density (ENFD) and related sweat gland nerve fiber density testing from skin biopsy to evaluate small-fiber neuropathy. It governs Capital BlueCross determinations for members when performed for diagnostic purposes.
Key ActionObtain prior authorization and document clinical evaluation including bedside sensory testing and normal nerve conduction studies before requesting skin biopsy for ENFD when confirming small-fiber neuropathy.
No material clinical or coverage changes in this revision.
95%-97%specificity of ENFD reported
45%-90%sensitivity range
<8 fibers/mmreported dorsal foot threshold
350 µminter-fiber distance
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
3 mm
punch biopsy size
~35,000EFNS experience cases
Coverage Criteria for Nerve Fiber Density Testing
Initial diagnostic coverage
Covered when ALL of the following are met:
Required clinical conditions: a) Individual presents with symptoms of painful sensory neuropathy; b) No history of a disorder known to predispose to painful neuropathy (e.g., diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy); c) Physical examination shows no evidence of findings consistent with large-fiber neuropathy (e.g., reduced or absent muscle-stretch reflexes or reduced proprioception/vibration); d) Electromyography and nerve-conduction studies are normal and show no evidence of large-fiber neuropathy.
Biopsy technique commonly uses a 3 mm punch and PGP 9.5 staining per policy documentation.
Diagnostic confirmation of SFN
Covered when guideline-supported clinical evaluation indicates need to confirm small fiber neuropathy:
Guideline-aligned indications: Patient has clinical features suggestive of small fiber neuropathy (e.g., painful or burning distal extremities, small-fiber sensory loss) AND noninvasive bedside testing (temperature or pinprick, 10-g monofilament, 128-Hz tuning fork) and autonomic testing where indicated are inconclusive or discordant.
Supported by EFNS/PNS, AAN/AANEM/AAPM&R, AACE/ACE and IMMPACT/NeuPSIG guidance; consider prior authorization when used to confirm SFN after noninvasive testing.
Limited utility / condition-specific caution
Considered experimental or low-yield in certain conditions or as sole diagnostic tool:
Low diagnostic yield or not routinely useful: Conditions where skin biopsy/IENFD has limited utility or low diagnostic yield per cited studies (examples include erythromelalgia, some fibromyalgia cohorts, select Fabry disease contexts, and certain post-infectious presentations) OR situations where biopsy alone is insufficient to establish diagnosis of pain conditions.
Examples: Mantyh et al. found <10% decreased ENFD in erythromelalgia; fibromyalgia studies show mixed findings and IENFD may not correlate with pain intensity; IENFD sensitivity/specificity vary in Fabry disease cohorts.
Guideline-supported clinical uses
Guideline support for skin biopsy: International expert panels and guideline bodies recommend that skin biopsy with IENFD measurement may be used to diagnose small fiber neuropathy, detect small fiber disease, and quantify loss of skin innervation; NeuPSIG recommends skin biopsy to determine IENFD in patients with clinical signs of small fiber dysfunction (level B) and measurement may be used in follow-up for diabetic patients (level C).
References include International Expert Panel on Neuropathy in Fabry Disease; IMMPACT; NeuPSIG; labs performing LDTs must validate assays per CLIA '88.
Measurement of sweat gland nerve fiber density (SGNFD or sweat gland innervation index) DOES NOT MEET COVERAGE CRITERIA. The policy explicitly limits coverage to epidermal (intraepidermal) nerve fiber density (ENFD/IENFD) for diagnosis of small-fiber neuropathy and states that sweat-gland–based measurements do not meet coverage criteria.
Supporting literature describes methods to quantify sweat-gland innervation and indicates potential research or complementary use in evaluating sudomotor dysfunction, but those techniques are not covered under this policy.
Skin or nerve biopsy is not required when there are accurate laboratory diagnostic tests available for a condition. The policy cites guideline guidance noting that when validated laboratory testing exists (for example, for Fabry disease), biopsy is unnecessary for diagnosis.
When laboratory tests provide a definitive diagnosis, biopsy may detect subclinical small-fiber involvement but is not required for diagnostic confirmation and therefore is not routinely indicated as part of initial diagnostic workup.
For Fabry disease specifically, expert panel recommendations state that skin or nerve biopsies are not required for diagnosis given the availability of accurate laboratory diagnostic testing; skin biopsy may identify small-fiber disease in asymptomatic individuals and can quantify loss of innervation but is not necessary to establish the diagnosis.
The policy explicitly states that measurement of sweat gland nerve fiber density does not meet coverage criteria. Additionally, evidence summarized in the document indicates that while techniques for assessing sweat gland innervation exist and may correlate with diabetic neuropathy severity, these assessments remain outside the scope of covered indications.
Skin biopsy is also described as not useful for certain pain syndromes (see other sections) and sweat-gland measurements are not accepted as covered diagnostic tests under this policy.
Skin biopsy performed solely to diagnose pain conditions without supportive clinical or functional testing is not supported. The policy emphasizes that IENFD has limited ability to diagnose pain syndromes on its own and should not be used in isolation to diagnose conditions such as erythromelalgia, where functional testing is more informative.
As a result, requests for biopsy intended only to explain pain without prior noninvasive assessment and concordant clinical findings are unlikely to meet coverage criteria.
Procedure Codes and Coding Notes
Applicable CPT Procedure CodesCPT
88313
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry.
88341
Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88342
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
88344
Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure.
88346
Immunofluorescence, per specimen; initial single antibody stain procedure.
88350
Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88356
Morphometric analysis; nerve
IENF density / inter-fiber distance — reported thresholds
Reported dorsal-foot thresholdIENF density < 8 fibers/mm at the dorsal foot associated with high sensitivity/specificity for SFSN in selected cohorts
Inter-fiber denervated stretchPresence of a denervated epidermal stretch > 350 µm improves diagnostic efficiency (AUC=0.85; sensitivity 74%, specificity 94%)
Specificity range in ankle studiesSpecificity reported 95%–97.5% across identified studies
Sensitivity variabilitySensitivity in ankle studies ranged widely (24%–100%) depending on population and criteria
Normative fifth-percentile referenceFifth percentile IENF density formula reported: 7.6156 - 0.0769 x age (years) + 1.5506 x gender (woman=1; man=0)
Provider Actions, Documentation, and Authorization
Prior Authorization
Provider Actions and Authorization Summary
Coverage for epidermal nerve fiber density (ENFD) measurement from a skin biopsy is contingent on meeting specific clinical criteria. ENFD testing is considered covered only when all coverage conditions are satisfied; tests performed for other indications will be denied. Prior authorization is advised for confirmatory skin biopsy requests to ensure criteria are met before service delivery. Providers should document the clinical rationale, prior noninvasive testing, and relevant diagnostic findings to support medical necessity. Specific CPT procedure codes related to processing, staining, immunohistochemistry/immunofluorescence, and morphometric nerve analysis require appropriate billing authorization and must be submitted in accordance with payer guidance. Clinical context (for example, distal symmetric polyneuropathy, suspected small-fiber neuropathy, or metabolic/pre-diabetes evaluation) may affect authorization decisions — specialty society recommendations endorse selective use of skin biopsy in these contexts. Laboratories performing intraepidermal nerve fiber density testing commonly use validated laboratory-developed tests (LDTs) under CLIA high-complexity rules; providers should verify that the performing lab maintains appropriate validation and reporting practices.
Coverage contingent on clinical criteria: ENFD measurement from skin biopsy MEETS COVERAGE CRITERIA only when ALL of the following are documented: (a) symptoms of painful sensory neuropathy; (b) no history of a disorder known to predispose to painful neuropathy (e.g., diabetic, toxic, HIV, celiac, inherited); (c) physical exam without signs of large-fiber neuropathy (no reduced/absent reflexes, preserved proprioception/vibration); (d) normal electromyography and nerve-conduction studies with no evidence of large-fiber neuropathy. Tests outside these indications DO NOT MEET COVERAGE CRITERIA.
Background and Context
Neuropathy refers to dysfunction of peripheral nerves causing numbness, pain, or weakness and can result from infections, trauma, or metabolic disorders such as diabetes. Small-fiber neuropathy affects epidermal sensory and autonomic nerve terminals and may produce painful burning sensations and small-fiber sensory loss.
Skin punch biopsy with PGP 9.5 immunostaining and measurement of intraepidermal/epidermal nerve fiber density (IENFD/ENFD) is a validated method to detect small-fiber sensory pathology and is supported by specialty guidance for use in selected clinical contexts when electrophysiologic testing is normal.
However, the policy limits coverage: ENFD measurement from skin biopsy meets coverage criteria only when specific clinical conditions are satisfied (symptoms of painful sensory neuropathy, absence of disorders known to predispose to painful neuropathy, no evidence of large-fiber neuropathy on exam, and normal EMG/nerve conduction studies).
Definitions and Abbreviations
ENFD / IENFD (definition and role)
DefinitionEpidermal (intraepidermal) nerve fiber density measured from skin biopsy stained with PGP 9.5 to quantify small sensory nerve fibers in the epidermis.
PurposeUsed to detect and quantify loss of small sensory nerve fibers in suspected small fiber neuropathy.
Technique noteTypically performed on distal-leg/ankle punch biopsy specimens with PGP 9.5 immunostaining and morphometric counting rules.
Clinical roleSupports diagnosis when electrophysiologic studies are normal and clinical suspicion for SFN persists.
SGNFD / SGII (definition and notes)
DefinitionSweat gland nerve fiber density (SGNFD) or sweat gland innervation index (SGII): structural measure of sudomotor innervation assessed from skin biopsy preparations.
Key ActionObtain prior authorization and document clinical evaluation including bedside sensory testing and normal nerve conduction studies before requesting skin biopsy for ENFD when confirming small-fiber neuropathy.
Prior authorization advised: Obtain prior authorization for skin biopsy/IENFD measurement to confirm small-fiber neuropathy, especially when used to confirm diagnosis in selected patients per specialty society guidance.
Noninvasive testing recommended before biopsy: Document prior bedside testing of small- and large-fiber function (e.g., 10-g monofilament, 128-Hz tuning fork, temperature or pinprick testing) and autonomic testing as clinically indicated; these assessments should be completed and recorded prior to biopsy when appropriate.
Required clinical assessment documentation: Include history of neuropathic symptoms, absence of disorders predisposing to painful neuropathy, focused neurologic exam findings (reflexes, vibration, proprioception), results of EMG/nerve conduction studies, prior bedside sensory testing, and rationale for biopsy (e.g., persistent symptoms with normal NCS/EMG).
Clinical-context dependence may affect authorization: Authorization decisions may consider guideline-recommended contexts (e.g., distal symmetric polyneuropathy, suspected small-fiber sensory neuropathy, metabolic syndrome/prediabetes) and may require correlation with specialty recommendations that endorse selective use of skin biopsy.
Procedure codes require billing authorization: CPT codes commonly associated with skin biopsy specimen processing and analysis include (but are not limited to) 88313 (special stain), 88342/88341/88344 (immunohistochemistry), 88346/88350 (immunofluorescence), and 88356 (morphometric analysis; nerve). Ensure these codes are authorized and documented per payer billing rules.
Coding and laboratory validation notes: Many labs perform IENFD testing as laboratory-developed tests (LDTs) and validate under CLIA high-complexity standards. FDA clearance is not required for LDTs currently; however, providers should confirm the performing laboratory's validation and reporting methods and include lab identification in the documentation.
Denial triggers and documentation risk: ENFD measurement will be denied if documentation does not support the required clinical criteria, if there is a history of a predisposing disorder, evidence of large-fiber neuropathy, or if prior noninvasive testing and EMG/NCS results are not provided.
Provider action summary: Before ordering biopsy, perform and document recommended noninvasive assessments, review patient history for predisposing conditions, obtain EMG/NCS as indicated, and secure prior authorization with submission of supporting documentation and intended CPT billing codes.
Note
Prior Authorization Advised; Specialty Society Recommendations
Skin biopsy and IENFD measurement are recommended by multiple specialty societies as a confirmatory test for small-fiber neuropathy in selected patients. Prior authorization is advised to confirm that clinical criteria and guideline-concordant assessments have been completed prior to testing. Authorization may be influenced by the clinical context and guideline recommendations.
Society guidance supports selective use of skin biopsy to confirm SFN when clinical signs of small-fiber dysfunction are present and other testing (EMG/NCS) is normal.
Autonomic testing should be considered when polyneuropathy is suspected to document autonomic dysfunction (AAN/AANEM/AAPM&R).
EFNS/PNS and other groups recommend distal leg skin biopsy with quantification of IENF density using standard counting rules for SFN assessment.
Billing Rule
Billing and Coding Authorization Required
Procedure and laboratory codes related to skin biopsy analysis must be billed with appropriate authorization and supported by documentation. Providers should include the specific CPT codes on authorization requests and claims and confirm laboratory validation status.
Relevant CPT codes (examples) to include on authorization/claims: 88313, 88341, 88342, 88344, 88346, 88350, 88356.
List codes on the prior authorization request and attach clinical documentation supporting medical necessity.
Confirm the performing laboratory's CLIA certification and validation of any laboratory-developed tests used for IENFD measurement.
Documentation Required
Coding and Laboratory Validation Notes
Laboratory-developed tests (LDTs) for IENFD are regulated under CLIA as high-complexity tests. FDA clearance is not required for clinical use of many LDTs; however, labs must validate their assays and report methods. Providers should document the performing laboratory and validation evidence when available.
Labs typically use PGP 9.5 immunostaining and morphometric analysis to quantify intraepidermal nerve fibers; these methods should be validated per CLIA standards.
Providers may request lab validation documentation or CLIA certificate if needed for prior authorization.
Clinical correlationSGNFD/SGII differentiates diabetic subjects from controls and correlates with sudomotor symptoms and examination scores.
Technique variationAlternate staining (PGP 9.5 with Congo red counterstain) can reduce measurement variability for sweat gland area assessments.
Intraepidermal nerve fiber density (IENFD)
DefinitionMorphometric quantification of intraepidermal nerve fibers from distal skin biopsy used to diagnose small fiber neuropathy (IENFD).
Guideline endorsementEFNS/PNS and other specialty bodies endorse distal-leg skin biopsy with agreed counting rules as a reliable technique to assess SFN.
Clinical implicationIENFD inversely correlates with thermal detection thresholds and is reduced in symptomatic patients even when NCS are normal.
Safety/data3-mm ankle punch biopsy is considered safe; EFNS reports ~35,000 biopsies with low incidence of non-serious side effects (0.19%).
Autonomic testing (definition and guidance)
DefinitionPhysiologic autonomic testing: tests to document autonomic nervous system dysfunction recommended in evaluation of polyneuropathy.
Guideline recommendationAAN/AANEM/AAPM&R: 'Autonomic testing should be considered in the evaluation of patients with polyneuropathy to document autonomic nervous system dysfunction (Level B).',
Role before biopsyAutonomic testing is part of the noninvasive assessments that may be done prior to considering skin biopsy when autonomic dysfunction is suspected.
DefinitionIENFD: histological quantification of epidermal nerve fibers from skin biopsy used to diagnose small fiber neuropathy.
Use in follow-upNeuPSIG: measurement of IENFD may be used in follow-up and to detect treatment response in diabetic patients with SFN (level C).
Diagnostic recommendationNeuPSIG/IMMPACT: perform skin biopsy with appropriate processing and image analysis in patients with clinical signs of small fiber dysfunction (level B).